Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Simon Baldacci (Lille, France), Simon Baldacci, Zoulika Kherrouche, Luc Stoven, Elisabeth Werkmeister, Nathalie Marchand, David Tulasne, Alexis Cortot. Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer. Eur Respir J 2015; 46: Suppl. 59, 4981

Member's Comments

No comment yet.

Related content which might interest you: Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017 RBM5 overexpression reverses acquired resistance to gefitinib in PC9/AB2 NSCLC cells Source: International Congress 2016 – Late-breaking translational research in lung cancer Year: 2016 Noninvasive detection of EGFR T790M mutation in gefitinib resistant non-small cell lung cancer using mutant-enriched PCR Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Nonsmall cell lung cancer Source: Eur Respir Rev 2013; 22: 33-36 Year: 2013 Glucocorticoid reduces pemetrexed sensitivity by mediating senescence-associated secretory phenotype in Bcl-2 dependent manner in non-small-cell lung cancer Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 EGFR mutations determine EGFR-MET crosstalk and MET inhibition in lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 European mapping of EGFR mutation test and EGFR tyrosine kinase inhibitors availability in thoracic oncology Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Clinical profile of newly diagnosed patients of non small cell carcinima with epidermal growth factor receptor positivity on oral tyrosine kinase inhibitor therapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015